<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00970957</url>
  </required_header>
  <id_info>
    <org_study_id>IOBA-03-2008</org_study_id>
    <secondary_id>EUDRA -CT 2008-005789-30</secondary_id>
    <nct_id>NCT00970957</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of Bevacizumab Intravitreal Injections in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion</brief_title>
  <acronym>EBOVER</acronym>
  <official_title>Study of the Safety and Efficacy of Bevacizumab Intravitreal Injections for the Treatment of Macular Edema Secondary to Retinal Vein Occlusions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA</source>
  <brief_summary>
    <textblock>
      Lack of an effective treatment for macular edema secondary to central retinal vein occlusion&#xD;
      and the bad response to grid laser treatment in patients with macular edema secondary to&#xD;
      branch retinal vein occlusion, together with the high incidence of the pathology and the&#xD;
      great functional loss in the patients that suffer from it has motivated the search for new&#xD;
      therapeutic approaches.&#xD;
&#xD;
      In recent times, intravitreal bevacizumab has been tested in clinical practice in small&#xD;
      series of patients with this pathology, whether as first treatment or after failure of grid&#xD;
      laser treatment with good functional results in short series.&#xD;
&#xD;
      However, no retreatment information is available, although preliminary results from published&#xD;
      series are good.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best corrected visual acuity assessed as described in the Early Treatment for Diabetes Retinopathy Study (ETDRS)</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Macular Subcentral Field Thickness assessed by Ocular coherence tomography</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Macular Edema</condition>
  <condition>Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>Central RVO - Macular edema - Avastin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Macular edema secondary to CENTRAL Retinal Vein Occlusion that will be treated with intravitreal injection of avastin once per month during the first 3 months. Re-treatments will be given as per protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Central RVO - Macular edema - Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients with Macular edema secondary to CENTRAL Retinal Vein Occlusion that will have a sham procedure performed. Injection without needle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Branch RVO - Macular edema - Avastin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Macular edema secondary to BRANCH Retinal Vein Occlusion that will be treated with intravitreal injection of avastin once per month during the first 3 months. Re-treatments will be given as per protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Branch RVO - Macular edema - Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients with Macular edema secondary to BRANCH Retinal Vein Occlusion that will have a sham procedure performed. Injection without needle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avastin Intravitreal Injection</intervention_name>
    <description>Intravitreal injection of 1.25mg Avastin (Bevacizumab) per month, during the first 3 months. Retreatments will be required if visual acuity or macular edema thickness worsen as defined per protocol</description>
    <arm_group_label>Branch RVO - Macular edema - Avastin</arm_group_label>
    <arm_group_label>Central RVO - Macular edema - Avastin</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sham Avastin Intravitreal Injection</intervention_name>
    <description>Intravitreal Injection simulation with a syringe without needle. The rest of the procedure remains the same as if intravitreal injection were to be performed (antibiotic prophylaxis, local anesthesia, ...).</description>
    <arm_group_label>Branch RVO - Macular edema - Sham</arm_group_label>
    <arm_group_label>Central RVO - Macular edema - Sham</arm_group_label>
    <other_name>Sham</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient male or female 18 years old or more&#xD;
&#xD;
          -  Foveal macular edema secondary to Retinal Vein Occlusion confirmed by Fluorescein&#xD;
             angiography and Optical Coherence Tomography, with a subcentral field thickness of at&#xD;
             least 250 microns&#xD;
&#xD;
          -  Patients with best corrected visual acuity loss within the last 6 months of evolution,&#xD;
             caused by the macular edema as stated by investigator´s judgement.&#xD;
&#xD;
          -  Best corrected visual acuity tested by ETDRS within 20/40 and 20/400 in the study eye.&#xD;
&#xD;
          -  Signed Informed consent.&#xD;
&#xD;
          -  Signed Data Protection Consent.&#xD;
&#xD;
          -  Negative pregnancy test before entering the study for childbearing potential women,&#xD;
             who must commit to use a medically accepted contraceptive method for the whole study.&#xD;
&#xD;
          -  Macular Subcentral field assessed by Ocular coherence tomography of at least 250&#xD;
             microns thick.&#xD;
&#xD;
          -  No presence of eye opacities that may prevent fundus exploration. No condition that&#xD;
             may prevent correct eye dilation.&#xD;
&#xD;
          -  No known allergy to fluorescein.&#xD;
&#xD;
          -  Only an eye per patient will be included in the study,even if both eyes have the&#xD;
             pathology.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Macular edema secondary to any other condition such as: diabetes retinopathy,&#xD;
             hypertension, Juxtafoveal telangiectasia, ...&#xD;
&#xD;
          -  Any previous treatment for macular edema such as photocoagulation, vitrectomy,&#xD;
             triamcinolone, radial optic neurotomy, ... in the study eye.&#xD;
&#xD;
          -  Any ocular illness thay may be associated to increased/high levels of VEGF (Age&#xD;
             related macular degeneration, Diabetes retinopathy, Uveitis, ...)&#xD;
&#xD;
          -  Systemical illnesses thay may be associated to increased/high levels of VEGF (e.g.&#xD;
             tumours).&#xD;
&#xD;
          -  Medical history of brain vascular episodes (stroke), ictus, angor pectoris or&#xD;
             myocardial infarct within 3 months before study inclusion.&#xD;
&#xD;
          -  Pregnancy or nursing.&#xD;
&#xD;
          -  Hypersensibility known or suspected to Bevacizumab, his excipients or any related&#xD;
             molecule.&#xD;
&#xD;
          -  Uncontrolled hypertension refractary to medical treatment.&#xD;
&#xD;
          -  Participation in any other trial or study within the last 3 months (minerals and&#xD;
             vitamins excluded) or treatment with anti-VEGF in the non-study eye within the&#xD;
             previous 3 months.&#xD;
&#xD;
          -  Tractional maculopathy and/or epiretinal membrane assessed by Ocular Coherence&#xD;
             Tomography.&#xD;
&#xD;
          -  Media opacities that don´t allow correct eye exploration and fundus&#xD;
             examination/photographs.&#xD;
&#xD;
          -  Cataract surgery / Yag capsulotomy within the previous 6 months.&#xD;
&#xD;
          -  Filtration surgery.&#xD;
&#xD;
          -  Previous medical history of ocular illnesses as: viral infections, inflammatory&#xD;
             pathology, serous central choroidopathy, retinal detachment or any other illness that&#xD;
             may have an influence in visual acuity.&#xD;
&#xD;
          -  Presence of foveal atrophy, severe pigmentary changes, dense subfoveal haemorrhages,&#xD;
             confluent subfoveal hard exudates or any other condition that may influence functional&#xD;
             recovery of the macular edema.&#xD;
&#xD;
          -  Cataract that may be responsible for additional visual acuity loss of more than 2/10.&#xD;
&#xD;
          -  Medically uncontrolled intraocular pressure higher than 25 mm Hg.&#xD;
&#xD;
          -  External ocular illnesses active at inclusion as: conjunctivitis, blepharitis, eye&#xD;
             sore, ...&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>María Isabel López Gálvez, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IOBA - Instituto Universitario de Oftalmobiología Aplicada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Provincial Conxo - Fundación IDICHUS</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>La Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Reina Sofía</name>
      <address>
        <city>Espinardo</city>
        <state>Murcia</state>
        <zip>30100</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31080</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Oftalmológico de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Vall D´Hebrón</name>
      <address>
        <city>Barcelona</city>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de Valme</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Universitario de Oftalmobiología Aplicada</name>
      <address>
        <city>Valladolid</city>
        <zip>47011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>September 2, 2009</study_first_submitted>
  <study_first_submitted_qc>September 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2009</study_first_posted>
  <last_update_submitted>March 18, 2014</last_update_submitted>
  <last_update_submitted_qc>March 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Macular edema</keyword>
  <keyword>Retinal Vein Occlusion</keyword>
  <keyword>Bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

